Ewing Tumor Biology: Perspectives for Innovative Treatment Approaches View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2003

AUTHORS

Heinrich Kovar

ABSTRACT

The Ewing’s sarcoma family of tumors (EFT) is a group of malignancies affecting bone and soft tissue in adolescents. It is characterized by a unique gene rearrangement between theEWSgene and anetstranscription factor gene. EFT can be cured with conventional multi modal treatment, however, about 40% of patients still succumb to the disease. Relapses can be observed more than 5 years after the end of primary treatment suggesting persistence of minimal residual disease (MRD). Due to the still enigmatic nature of EFT histogenesis the phenotype of EFT stem cells and of dormant tumor cells remains unknown. The most frequent fusion product associated with EFT, EWS-FLIT, is the founding member of a whole class of similarly structured chimeric proteins associated with a variety of human sarcomas and also specific leukemias. The corresponding gene rearrangement constitutes a rate limiting step in oncogenesis as implied by the high association of EFT withEWS-ETSfusions, strong selective pressure for maintenance of a correct reading frame in the tumors, and by experimental data confirming the transforming and tumorigenic potential of EWS-FLI1. Understanding the biology ofEWS-ETSgene fusions and its interplay with essential cellular pathways regulating cell growth, apoptosis, differentiation, genomic integrity, and treatment resistance may unravel specifically vulnerable sites for therapeutic targeting. This review summarizes the current knowledge about the EWS-FLI1 pathway in EFT and provides some ideas as to how this knowledge may be translated into innovative treatment approaches. More... »

PAGES

27-37

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4615-0081-0_4

DOI

http://dx.doi.org/10.1007/978-1-4615-0081-0_4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052462623

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/12908547


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chromatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Genetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oncogene Proteins, Fusion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenotype", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Precipitin Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Protein c-fli-1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-ets", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "RNA-Binding Protein EWS", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sarcoma, Ewing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcription Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transcription, Genetic", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Children\u2019s Cancer Research Institute, St. Anna Kinderspital, Vienna", 
          "id": "http://www.grid.ac/institutes/grid.416346.2", 
          "name": [
            "Children\u2019s Cancer Research Institute, St. Anna Kinderspital, Vienna"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kovar", 
        "givenName": "Heinrich", 
        "id": "sg:person.0741362200.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741362200.35"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2003", 
    "datePublishedReg": "2003-01-01", 
    "description": "The Ewing\u2019s sarcoma family of tumors (EFT) is a group of malignancies affecting bone and soft tissue in adolescents. It is characterized by a unique gene rearrangement between theEWSgene and anetstranscription factor gene. EFT can be cured with conventional multi modal treatment, however, about 40% of patients still succumb to the disease. Relapses can be observed more than 5 years after the end of primary treatment suggesting persistence of minimal residual disease (MRD). Due to the still enigmatic nature of EFT histogenesis the phenotype of EFT stem cells and of dormant tumor cells remains unknown. The most frequent fusion product associated with EFT, EWS-FLIT, is the founding member of a whole class of similarly structured chimeric proteins associated with a variety of human sarcomas and also specific leukemias. The corresponding gene rearrangement constitutes a rate limiting step in oncogenesis as implied by the high association of EFT withEWS-ETSfusions, strong selective pressure for maintenance of a correct reading frame in the tumors, and by experimental data confirming the transforming and tumorigenic potential of EWS-FLI1. Understanding the biology ofEWS-ETSgene fusions and its interplay with essential cellular pathways regulating cell growth, apoptosis, differentiation, genomic integrity, and treatment resistance may unravel specifically vulnerable sites for therapeutic targeting. This review summarizes the current knowledge about the EWS-FLI1 pathway in EFT and provides some ideas as to how this knowledge may be translated into innovative treatment approaches.", 
    "editor": [
      {
        "familyName": "Llombart-Bosch", 
        "givenName": "Antonio", 
        "type": "Person"
      }, 
      {
        "familyName": "Felipo", 
        "givenName": "Vicente", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4615-0081-0_4", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4613-4914-3", 
        "978-1-4615-0081-0"
      ], 
      "name": "New Trends in Cancer for the 21stCentury", 
      "type": "Book"
    }, 
    "keywords": [
      "minimal residual disease", 
      "innovative treatment approaches", 
      "sarcoma family", 
      "treatment approaches", 
      "multi-modal treatment", 
      "gene rearrangements", 
      "Ewing's sarcoma family", 
      "group of malignancies", 
      "dormant tumor cells", 
      "residual disease", 
      "primary treatment", 
      "treatment resistance", 
      "therapeutic targeting", 
      "unique gene rearrangements", 
      "tumor biology", 
      "human sarcomas", 
      "tumor cells", 
      "soft tissue", 
      "essential cellular pathways", 
      "strong selective pressure", 
      "high association", 
      "tumorigenic potential", 
      "correct reading frame", 
      "specific leukemias", 
      "tumors", 
      "EWS-FLI1", 
      "disease", 
      "stem cells", 
      "genomic integrity", 
      "current knowledge", 
      "reading frame", 
      "cell growth", 
      "cellular pathways", 
      "factor genes", 
      "chimeric protein", 
      "selective pressure", 
      "treatment", 
      "modal treatment", 
      "vulnerable sites", 
      "cells", 
      "relapse", 
      "patients", 
      "fusion products", 
      "malignancy", 
      "sarcoma", 
      "leukemia", 
      "pathway", 
      "histogenesis", 
      "bone", 
      "apoptosis", 
      "adolescents", 
      "tissue", 
      "oncogenesis", 
      "association", 
      "phenotype", 
      "rearrangement", 
      "group", 
      "review", 
      "targeting", 
      "enigmatic nature", 
      "years", 
      "genes", 
      "biology", 
      "differentiation", 
      "protein", 
      "EFT", 
      "knowledge", 
      "persistence", 
      "rate", 
      "resistance", 
      "maintenance", 
      "family", 
      "pressure", 
      "members", 
      "growth", 
      "fusion", 
      "data", 
      "sites", 
      "integrity", 
      "end", 
      "potential", 
      "interplay", 
      "variety", 
      "approach", 
      "frame", 
      "step", 
      "products", 
      "perspective", 
      "class", 
      "nature", 
      "experimental data", 
      "idea", 
      "whole class"
    ], 
    "name": "Ewing Tumor Biology: Perspectives for Innovative Treatment Approaches", 
    "pagination": "27-37", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052462623"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4615-0081-0_4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "12908547"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4615-0081-0_4", 
      "https://app.dimensions.ai/details/publication/pub.1052462623"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-08-04T17:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/chapter/chapter_32.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4615-0081-0_4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4615-0081-0_4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4615-0081-0_4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4615-0081-0_4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4615-0081-0_4'


 

This table displays all metadata directly associated to this object as RDF triples.

221 TRIPLES      22 PREDICATES      134 URIs      127 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4615-0081-0_4 schema:about N160a24e667204d6084b6b898d4d0ba8b
2 N26179febe89e4b058ab942c5d0e2f762
3 N28374baa3a4349d5ae65d71b5c2f223b
4 N7078d34ccb8545bab0c3802402aa068e
5 N7a1ae5c19b594e788eaf4ead5af37acb
6 N881a671ba30044a58cf04a54345a2b48
7 N8af10244968c47bf8017decd3a77e6d6
8 Na77da3c86a18437aa75a4a07349573aa
9 Nb1eb2e9a08f84ef3825cf1fe33939876
10 Nb30865dba1b3457e8a35a9ce4619b9e4
11 Nbebf0df0e21c48dc8431c340fd5623a1
12 Nc4bf3d9a919d456b895a023e124ff4f0
13 Nd68e2bedebe74e299bd8da953519b989
14 Nf3a66123332f4767804ac3dc38467dc2
15 Nff6691f693ff48b789267baa0c0dc932
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author Na41173924d9a467a9d49c2333b36123f
19 schema:datePublished 2003
20 schema:datePublishedReg 2003-01-01
21 schema:description The Ewing’s sarcoma family of tumors (EFT) is a group of malignancies affecting bone and soft tissue in adolescents. It is characterized by a unique gene rearrangement between theEWSgene and anetstranscription factor gene. EFT can be cured with conventional multi modal treatment, however, about 40% of patients still succumb to the disease. Relapses can be observed more than 5 years after the end of primary treatment suggesting persistence of minimal residual disease (MRD). Due to the still enigmatic nature of EFT histogenesis the phenotype of EFT stem cells and of dormant tumor cells remains unknown. The most frequent fusion product associated with EFT, EWS-FLIT, is the founding member of a whole class of similarly structured chimeric proteins associated with a variety of human sarcomas and also specific leukemias. The corresponding gene rearrangement constitutes a rate limiting step in oncogenesis as implied by the high association of EFT withEWS-ETSfusions, strong selective pressure for maintenance of a correct reading frame in the tumors, and by experimental data confirming the transforming and tumorigenic potential of EWS-FLI1. Understanding the biology ofEWS-ETSgene fusions and its interplay with essential cellular pathways regulating cell growth, apoptosis, differentiation, genomic integrity, and treatment resistance may unravel specifically vulnerable sites for therapeutic targeting. This review summarizes the current knowledge about the EWS-FLI1 pathway in EFT and provides some ideas as to how this knowledge may be translated into innovative treatment approaches.
22 schema:editor N7f17526ad47c4e61893108459ae015e1
23 schema:genre chapter
24 schema:isAccessibleForFree false
25 schema:isPartOf N03c682815fc14e35830965e9e4967d76
26 schema:keywords EFT
27 EWS-FLI1
28 Ewing's sarcoma family
29 adolescents
30 apoptosis
31 approach
32 association
33 biology
34 bone
35 cell growth
36 cells
37 cellular pathways
38 chimeric protein
39 class
40 correct reading frame
41 current knowledge
42 data
43 differentiation
44 disease
45 dormant tumor cells
46 end
47 enigmatic nature
48 essential cellular pathways
49 experimental data
50 factor genes
51 family
52 frame
53 fusion
54 fusion products
55 gene rearrangements
56 genes
57 genomic integrity
58 group
59 group of malignancies
60 growth
61 high association
62 histogenesis
63 human sarcomas
64 idea
65 innovative treatment approaches
66 integrity
67 interplay
68 knowledge
69 leukemia
70 maintenance
71 malignancy
72 members
73 minimal residual disease
74 modal treatment
75 multi-modal treatment
76 nature
77 oncogenesis
78 pathway
79 patients
80 persistence
81 perspective
82 phenotype
83 potential
84 pressure
85 primary treatment
86 products
87 protein
88 rate
89 reading frame
90 rearrangement
91 relapse
92 residual disease
93 resistance
94 review
95 sarcoma
96 sarcoma family
97 selective pressure
98 sites
99 soft tissue
100 specific leukemias
101 stem cells
102 step
103 strong selective pressure
104 targeting
105 therapeutic targeting
106 tissue
107 treatment
108 treatment approaches
109 treatment resistance
110 tumor biology
111 tumor cells
112 tumorigenic potential
113 tumors
114 unique gene rearrangements
115 variety
116 vulnerable sites
117 whole class
118 years
119 schema:name Ewing Tumor Biology: Perspectives for Innovative Treatment Approaches
120 schema:pagination 27-37
121 schema:productId N6615c458f56346e78a918b3b378bc692
122 Nc4884d83606c46a088fa2e61d3f16c2e
123 Ncdb47aabba2a4e59a896240ed4502b33
124 schema:publisher Nb0767fcfc3ee43f698b53adaa3385e2f
125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052462623
126 https://doi.org/10.1007/978-1-4615-0081-0_4
127 schema:sdDatePublished 2022-08-04T17:18
128 schema:sdLicense https://scigraph.springernature.com/explorer/license/
129 schema:sdPublisher N0e95bfa639f14ced85b7ccec338b31d7
130 schema:url https://doi.org/10.1007/978-1-4615-0081-0_4
131 sgo:license sg:explorer/license/
132 sgo:sdDataset chapters
133 rdf:type schema:Chapter
134 N0214dee1496c492aafdfe74935da9f55 schema:familyName Felipo
135 schema:givenName Vicente
136 rdf:type schema:Person
137 N03c682815fc14e35830965e9e4967d76 schema:isbn 978-1-4613-4914-3
138 978-1-4615-0081-0
139 schema:name New Trends in Cancer for the 21stCentury
140 rdf:type schema:Book
141 N0e95bfa639f14ced85b7ccec338b31d7 schema:name Springer Nature - SN SciGraph project
142 rdf:type schema:Organization
143 N160a24e667204d6084b6b898d4d0ba8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Models, Genetic
145 rdf:type schema:DefinedTerm
146 N26179febe89e4b058ab942c5d0e2f762 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name RNA-Binding Protein EWS
148 rdf:type schema:DefinedTerm
149 N28374baa3a4349d5ae65d71b5c2f223b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Oncogene Proteins, Fusion
151 rdf:type schema:DefinedTerm
152 N2f6731a291eb46ad9b3fd98c4d3268a8 schema:familyName Llombart-Bosch
153 schema:givenName Antonio
154 rdf:type schema:Person
155 N6615c458f56346e78a918b3b378bc692 schema:name dimensions_id
156 schema:value pub.1052462623
157 rdf:type schema:PropertyValue
158 N7078d34ccb8545bab0c3802402aa068e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Sarcoma, Ewing
160 rdf:type schema:DefinedTerm
161 N7a1ae5c19b594e788eaf4ead5af37acb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Chromatin
163 rdf:type schema:DefinedTerm
164 N7f17526ad47c4e61893108459ae015e1 rdf:first N2f6731a291eb46ad9b3fd98c4d3268a8
165 rdf:rest Nd88156eba0114106823c48adfcae116d
166 N881a671ba30044a58cf04a54345a2b48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Animals
168 rdf:type schema:DefinedTerm
169 N8af10244968c47bf8017decd3a77e6d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Proto-Oncogene Protein c-fli-1
171 rdf:type schema:DefinedTerm
172 Na41173924d9a467a9d49c2333b36123f rdf:first sg:person.0741362200.35
173 rdf:rest rdf:nil
174 Na77da3c86a18437aa75a4a07349573aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Transcription, Genetic
176 rdf:type schema:DefinedTerm
177 Nb0767fcfc3ee43f698b53adaa3385e2f schema:name Springer Nature
178 rdf:type schema:Organisation
179 Nb1eb2e9a08f84ef3825cf1fe33939876 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Phenotype
181 rdf:type schema:DefinedTerm
182 Nb30865dba1b3457e8a35a9ce4619b9e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Humans
184 rdf:type schema:DefinedTerm
185 Nbebf0df0e21c48dc8431c340fd5623a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Precipitin Tests
187 rdf:type schema:DefinedTerm
188 Nc4884d83606c46a088fa2e61d3f16c2e schema:name pubmed_id
189 schema:value 12908547
190 rdf:type schema:PropertyValue
191 Nc4bf3d9a919d456b895a023e124ff4f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Proto-Oncogene Proteins c-ets
193 rdf:type schema:DefinedTerm
194 Ncdb47aabba2a4e59a896240ed4502b33 schema:name doi
195 schema:value 10.1007/978-1-4615-0081-0_4
196 rdf:type schema:PropertyValue
197 Nd68e2bedebe74e299bd8da953519b989 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Apoptosis
199 rdf:type schema:DefinedTerm
200 Nd88156eba0114106823c48adfcae116d rdf:first N0214dee1496c492aafdfe74935da9f55
201 rdf:rest rdf:nil
202 Nf3a66123332f4767804ac3dc38467dc2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Proto-Oncogene Proteins
204 rdf:type schema:DefinedTerm
205 Nff6691f693ff48b789267baa0c0dc932 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Transcription Factors
207 rdf:type schema:DefinedTerm
208 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
209 schema:name Medical and Health Sciences
210 rdf:type schema:DefinedTerm
211 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
212 schema:name Oncology and Carcinogenesis
213 rdf:type schema:DefinedTerm
214 sg:person.0741362200.35 schema:affiliation grid-institutes:grid.416346.2
215 schema:familyName Kovar
216 schema:givenName Heinrich
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741362200.35
218 rdf:type schema:Person
219 grid-institutes:grid.416346.2 schema:alternateName Children’s Cancer Research Institute, St. Anna Kinderspital, Vienna
220 schema:name Children’s Cancer Research Institute, St. Anna Kinderspital, Vienna
221 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...